Methods of treating or preventing pruritis by blocking natriuretic polypeptide B

Patent metadata

Field	Value
Publication number	US-9987330-B2
Application number	US-201415039982-A
Country	US
Kind code	B2
Filing date	Dec 4, 2014
Priority date	Dec 5, 2013
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.

First claim

The invention claimed is:

1. A method of treating or reducing pruritis in a mammal in need thereof, the method comprising administering (a) HS-142-1 or (b) [Asu7,23′]b-ANA-(7-28)] in an amount effective to treat or reduce pruritis in the mammal.

2. The method of claim 1 , wherein the pruritis is associated with a fungal skin infection.

3. The method of claim 1 , wherein the pruritis is induced by a pruritogen selected from the group consisting of histamine, chloroquine, endothelin (ET-1), 2-methyl serotonin (5HT), SLIGRL-NH2 (PAR2), and compound 48/80 (48/80).

4. The method of claim 1 , wherein the pruritis is associated with renal failure.

5. The method of claim 1 , wherein the pruritis is associated with kidney dialysis.

6. The method of claim 1 , wherein the pruritis is mediated by interleukin (IL)-31.

7. The method of claim 1 , wherein the mammal is a human.

8. The method of claim 1 , wherein the pruritis is associated with a Trichomonas skin infection.

9. The method of claim 1 , wherein the pruritis is associated with eczema.

10. The method of claim 1 , wherein the pruritis is associated with psoriasis.

11. The method of claim 1 , wherein the pruritis is associated with acquired immune deficiency syndrome (AIDS).

12. The method of claim 1 , wherein the pruritis is associated with polycythemia vera.

13. The method of claim 1 , wherein the pruritis is associated with diabetes.

14. The method of claim 1 , wherein the pruritis is associated with hyperthyroidism.

15. The method of claim 1 , wherein the pruritis is associated with liver damage or liver disease.

16. The method of claim 1 , wherein the pruritis is associated with cancer.

17. The method of claim 1 , wherein the pruritis is associated with chemotherapy.

18. A method of treating or reducing pruritis in a mammal in need thereof, the method comprising administering [Asu7,23′]b-ANA-(7-28)] to the mammal in an amount effective to treat or reduce pruritis in the mammal.

19. The method of claim 18 , wherein the pruritis is induced by a pruritogen selected from the group consisting of histamine, chloroquine, endothelin (ET-1), 2-methyl serotonin (5HT), SLIGRL-NH2 (PAR2), and compound 48/80 (48/80).

20. The method of claim 18 , wherein the pruritis is associated with a fungal skin infection.

21. The method of claim 18 , wherein the pruritis is associated with a Trichomonas skin infection.

22. The method of claim 18 , wherein the pruritis is associated with eczema.

23. The method of claim 18 , wherein the pruritis is associated with psoriasis.

24. The method of claim 18 , wherein the pruritis is associated with renal failure.

25. The method of claim 18 , wherein the pruritis is associated with acquired immune deficiency syndrome (AIDS).

26. The method of claim 18 , wherein the pruritis is associated with polycythemia vera.

27. The method of claim 18 , wherein the pruritis is associated with diabetes.

28. The method of claim 18 , wherein the pruritis is associated with hyperthyroidism.

29. The method of claim 4 , wherein the pruritis is associated with liver damage or liver disease.

30. The method of claim 18 , wherein the pruritis is associated with cancer.

31. The method of claim 18 , wherein the pruritis is associated with chemotherapy.

32. The method of claim 18 , wherein the pruritis is associated with kidney dialysis.

33. The method of claim 18 , wherein the pruritis is mediated by interleukin (IL)-31.

34. The method of claim 18 , wherein the mammal is a human.

Assignees

• Us Health

Inventors

• Hoon Mark A
• Mishra Santosh K

Classifications

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• A61K47/62

  the modifying agent being a protein, peptide or polyamino acid · CPC title

• A01K2227/105

  Murine · CPC title

• C07K16/26

  against hormones {; against hormone releasing or inhibiting factors} · CPC title

• A61K38/1796

  for hormones (for neuromediators A61K38/1787) · CPC title